使用18F-氟胸苷PET对肾细胞癌中的细胞增殖进行体内成像。

In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET.

作者信息

Wong Peter K, Lee Sze Ting, Murone Carmel, Eng John, Lawrentschuk Nathan, Berlangieri Salvatore U, Pathmaraj Kunthi, O'Keefe Graeme J, Sachinidis John, Byrne Amanda J, Bolton Damien M, Davis Ian D, Scott Andrew M

机构信息

Department of Surgery and Urology, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia; Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia.

Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia; Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia; Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.

出版信息

Asia Ocean J Nucl Med Biol. 2014 Spring;2(1):3-11.

PMID:27408853

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4937709/

Abstract

OBJECTIVES

The ability to measure cellular proliferation non-invasively in renal cell carcinoma may allow prediction of tumour aggressiveness and response to therapy. The aim of this study was to evaluate the uptake of 18F-fluorothymidine (FLT) PET in renal cell carcinoma (RCC), and to compare this to 18F-fluorodeoxyglucose (FDG), and to an immunohistochemical measure of cellular proliferation (Ki-67).

METHODS

Twenty seven patients (16 male, 11 females; age 42-77) with newly diagnosed renal cell carcinoma suitable for resection were prospectively enrolled. All patients had preoperative FLT and FDG PET scans. Visual identification of tumour using FLT PET compared to normal kidney was facilitated by the use of a pre-operative contrast enhanced CT scan. After surgery tumour was taken for histologic analysis and immunohistochemical staining by Ki-67.

RESULTS

The SUVmax (maximum standardized uptake value) mean±SD for FLT in tumour was 2.59±1.27, compared to normal kidney (2.47±0.34). The mean SUVmax for FDG in tumour was similar to FLT (2.60±1.08). There was a significant correlation between FLT uptake and the immunohistochemical marker Ki-67 (r=0.72, P<0.0001) in RCC. Ki-67 proliferative index was mean ± SD of 13.3%±9.2 (range 2.2% - 36.3%).

CONCLUSION

There is detectable uptake of FLT in primary renal cell carcinoma, which correlates with cellular proliferation as assessed by Ki-67 labelling index. This finding has relevance to the use of FLT PET in molecular imaging studies of renal cell carcinoma biology.

摘要

目的

在肾细胞癌中无创测量细胞增殖的能力可能有助于预测肿瘤侵袭性及对治疗的反应。本研究的目的是评估¹⁸F-氟胸苷（FLT）PET在肾细胞癌（RCC）中的摄取情况，并将其与¹⁸F-氟脱氧葡萄糖（FDG）以及细胞增殖的免疫组化指标（Ki-67）进行比较。

方法

前瞻性纳入27例（16例男性，11例女性；年龄42 - 77岁）新诊断的适合手术切除的肾细胞癌患者。所有患者术前行FLT和FDG PET扫描。术前增强CT扫描有助于通过FLT PET视觉识别肿瘤与正常肾脏。术后取肿瘤组织进行组织学分析及Ki-67免疫组化染色。

结果

肿瘤中FLT的SUVmax（最大标准化摄取值）均值±标准差为2.59±1.27，而正常肾脏为2.47±0.34。肿瘤中FDG的平均SUVmax与FLT相似（2.60±1.08）。肾细胞癌中FLT摄取与免疫组化标志物Ki-67之间存在显著相关性（r = 0.72，P < 0.0001）。Ki-67增殖指数均值±标准差为13.3%±9.2（范围2.2% - 36.3%）。